EpiCypher is offering five fully funded EpiTitan™ Histone Peptide Array Screening & Services Grants, for which applications are to be submitted by September 10, 2014. Applications will be reviewed by an independant scientific community.
Epigenetics is the study of heritable changes in phenotype that exhibit no underlying changes in DNA sequence. Over the past several years there has been a significant increase in the number of epigenetic regulators as clinical targets, including Histone Deacetylases (HDAC), Bromodomain Proteins (BET), DOT1L, and EZH2. A number of these targets have FDA-approved drugs, or are in late stage clinical trials, to inhibit their function, demonstrating the adoption of supporting patients with diseases involving epigenetic targets.